معرفی
Dr. Zeyad Nassar is a Research Fellow at the University of Adelaide's South Australian Immunogenomics Cancer Institute and SAHMRI Prostate Cancer Research Group. His research focuses on prostate cancer, lipid metabolism, and drug discovery, with a particular emphasis on synthetic lethality and precision medicine. He has contributed to over 50 publications and secured grants from NHMRC, Cancer Australia, and the US Department of Defense. Dr. Nassar explores how lipid metabolism influences cancer progression and treatment resistance, aiming to identify novel therapeutic targets. His current projects include advancing synthetic lethality approaches for precision medicine and investigating diet interventions for mutation-specific prostate cancer therapies.
Education: PhD in cancer research, with MSc and BSc backgrounds in related fields (details not explicitly provided). Supervision: Eligible to supervise Masters and PhD students in prostate cancer and lipid metabolism research.
Research Contributions: Identified vulnerabilities in prostate cancer via synthetic lethality screens, studied fatty acid oxidation's role in treatment resistance, and developed patient-derived models for clinical trials. His work bridges laboratory discoveries with clinical applications, particularly in prostate cancer.
Awards/Grants: Competitive grants from NHMRC, Cancer Australia, and US DoD. Promoted to Academic Level (C) at the University of Adelaide in 2022.
Labs/Teams: Part of the SAHMRI Prostate Cancer Research Group, collaborating nationally and internationally on precision medicine initiatives.
